Browse > Article

Effects of Sojihwangamibang on Hyperlipidemia in Rats Induced by High Cholesterol Diet  

Yu, Mao-Lun (Department of Pathology, College of Oriental Medicine, Daejeon University)
Kim, Dong-Hee (Department of Pathology, College of Oriental Medicine, Daejeon University)
Publication Information
Journal of Physiology & Pathology in Korean Medicine / v.23, no.6, 2009 , pp. 1358-1367 More about this Journal
Abstract
This experimental study was designed to investigate the inhibitory effects of Sojihwangamibang on hyperlipidemia in rats induced by high cholesterol diet diet. Sprague- Dawley rats were divided into normal group, control group, SJB treated group. Obese rats were induced by high cholesterol diet treatment for 6 weeks including a oral administration of SJB for 4 weeks. In SJB group, serum total cholesterol, LDL cholesterol, triglyceride and glucose were significantly decreased, and HDL cholesterol was significantly increased compared with untreated control group. In SJB group, HMG-CoA and ACAT concentration of hepatic homogenate were significantly decreased compared with untreated control group. These results provide experimental evidence that SJB, applied currently in the clinical practice, appears to be effective for down-regulating risk factors of hyperlipidemia, and thus may be used as an objective information for the development of therapeutic agents.
Keywords
Sojihwangamibang(SJB); LDL cholesterol; HDL cholesterol; hyperlipidemia;
Citations & Related Records
연도 인용수 순위
  • Reference
1 National Cholesterol Education Program National Heart, Lung, and Blood Institute National Institutes of Health. Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), Executive Summary. NIH Publication No. 01-3670, 2001
2 Fedder, D.O., Koro, C.E., L, G.J. New national cholesterol education program III guidelines for primary prevention lipid-lowering drug therapy. Circulation 105: 152-156, 2002   DOI   ScienceOn
3 Westerterp, M., de Haan, W., Berb$\acute{e}$e, J.F., Havekes, L.M. Rensen PC. Endogenous apoC-I increases hyperlipidemia in apoE-knockout mice by stimulating VLDL production and inhibiting LPL. J Lipid Res. 247(6):1203-1211, 2006
4 Uhita, K., Masayuki, O., Ohno, K., Hashiguchi, M., Echizen, H., Rikihisa, T., Ogata hiroyasu. Drug Use Evaluation of Antidyslipidemic Agents at a Community Hospital in Japan. PSJ 122(7):499-506, 2002
5 Sato, N., Fujii, K., Yuge, O. In vivo and in vitro sevoflurane-induced lipid peroxidation in guinea-pig liver microsomes. 75(6):366-370, 1994
6 Yang, C.C., Kao, C.C. Cardiovascular diseases and the risk of venous thromboembolism: a hospital-based case-control sardy. J Chin Med Assoc. 70(3):103-109, 2007   DOI   ScienceOn
7 Kannel, W.B. High-density lipoproteins: epidemiologic profile and risks of coronary artery disease. Am J Cardiol. 52(4):9B-12B, 1983   DOI   ScienceOn
8 Shipley, M.J., Pocock, S.J., Marmot, M.G. Does plasma cholesterol concentration predict mortality from coronary heart disease in elderly people? 18 year follow up in Whitehall study. BMJ. 303(6794):89-92, 1991   DOI   ScienceOn
9 Fruchart, J.C., Duriez, P. Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. Drugs Today (Barc). 42(1):39-64, 2006   DOI   PUBMED   ScienceOn
10 Frick, M.H., Elo, O., Haapa, K., Heinonen, O.P., Heinsalmi, P., Helo, P., Huttunen, J.K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 317(20):1237-1245, 1987   DOI   PUBMED   ScienceOn
11 Tsutsumi, K., Inoue, Y., Murase, T. Effects of NO-1886, a lipoprotein lipase promoting agent, on homozygous and heterozygous Watanabe heritable hyperlipidaemic rabbits. Arzneimittelforschung. 50(2):118-121, 2000   PUBMED
12 Liang, K., Kim, C.H., Vaziri, N.D. HMG-CoA reductase inhibition reverses LCAT and LDL receptor deficiencies and improves HDL in rats with chronic renal failure.Am J Physiol Renal Physiol. 288(3):F539-544, 2005   DOI   PUBMED   ScienceOn
13 横山. 冠動脈疾患과 酸化스트레스. 炎症, pp 131-138, 2003
14 통계청. 2008 한국의 사회지표. 2009년 2월
15 Kim, J.Q., Song, J., Park, Y.B., Lee, H.K., Kim, Y.S., Ryoo, U.H., Heo, G.B. National cholesterol treatment guidelines in Korean population - setting-up the cutpoints for high blood cholesterol. J Korean Med Sci. 12: 17-22, 1997   DOI   PUBMED
16 Siegel-Axel, D., Daub, K., Seizer, P., Lindemann, S., Gawaz, M. Cardiovasc Res. Platelet lipoprotein interplay: trigger of foam cell formation and driver of atherosclerosis. 78(1):8-17, 2008   DOI   ScienceOn
17 정은아, 김윤경, 김남재, 김동현, 이상인. 가미과루해백황금탕의 항고지혈증 효과. 응용약물학회지 9: 104-111, 2001   과학기술학회마을
18 Vaziri, N.D., Liang, K. ACAT inhibition reverses LCAT deficiency and improves plasma HDL in chronic renal failure.Am J Physiol Renal Physiol. 287(5):F1038-1043, 2004   DOI   PUBMED
19 Vaziri, N.D., Liang, K. Up-regulation of acyl-coenzyme A:cholesterol acyltransferase (ACAT) in nephrotic syndrome. Kidney Int. 61(5):1769-1775, 2002   DOI   ScienceOn
20 Zoltowska, M., Delvin, E.E., Paradis, K., Seidman, E., Levy, E. Bile duct cells: a novel in vitro model for the study of lipid metabolism and bile acid production. Am J Physiol. 276(2 Pt 1):G407-414, 1999   PUBMED
21 Susan, M.D. and Darry, L.F. Normobaric oxygen toxicity of the lung. New. Engl. J. Med. 303: 76, 1980   DOI   ScienceOn
22 Jukema, J.W., Bruschke, A.V., van Boven, A.J., Reiber, J.H., Bal, E.T., Zwinderman, A.H., Jansen, H., Boerma, G.J., van Rappard, F.M., Lie, K.I., et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderat- ely elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS).Circulation. 91(10):2528-2540, 1995   DOI   PUBMED   ScienceOn
23 Miura, S., Saku, K. Therapies for raising high-density lipoprotein cholesterol. Intern Med. 46(7):339-340, 2007   DOI   ScienceOn
24 Schoenhagen, P., Tuzcu, E.M., Apperson-Hansen, C., Wang, C., Wolski, K., Lin, S., Sipahi, I., Nicholls, S.J., Magyar, W.A., Loyd, A., Churchill, T., Crowe, T., Nissen, S.E. Determinants of arterial wall remodeling during lipidlowering therapy: serial intravascular ultrasound observations from the Reversal of Atherosclerosis with Aggressive Lipid Lowering Therapy (REVERSAL) trial. Circulation. 113(24):2826-2834, 2006   DOI   ScienceOn
25 Chuang, P., Langone, A.J. Ezetimibe reduces low-density lipoprotein cholesterol (LDL-C) in renal transplant patients resistant to HMG-CoA reductase inhibitors. Am J Ther. 14(5):438-441, 2007   DOI   ScienceOn
26 Kjorholt, C., Akerfeldt, M.C., Biden, T.J., Laybutt, D.R. Chronic hyperglycemia, independent of plasma lipid levels, is sufficient for the loss of beta-cell differentiation and secretory function in the db/db mouse model of diabetes. Diabetes. 54(9):2755-2763, 2005   DOI   ScienceOn
27 Halliwell, B. Biochemical mechanism accounting for the toxic action of oxygen on living organisms. the key role of superoxide dismutase. Cell. Biol. Int. Rep. 2: 11, 1978   DOI   ScienceOn
28 Roberts, C.K., Liang, K., Barnard, R.J., Kim, C.H., Vaziri, N.D. HMG-CoA reductase, cholesterol 7alpha-hydroxylase, LDL receptor, SR-B1, and ACAT in diet-induced syndrome X.Kidney Int. 66(4):1503-1511, 2004   DOI   ScienceOn
29 Chun, S., Min, W., Park, H., Song, J., Kim, J., Min, Y., Kim, J., Lee, S. The risk groups for coronary heart disease in Koreans. Assessment by distribution of serum lipid concentrations. Clin Chem Lab Med 37: 969-974, 1999   DOI   ScienceOn
30 Igarashi, K., Tsuji, M., Nishimura, M., Horimoto, M. Improvement of endothelium-dependent coronary vasodilation after a single LDL apheresis in patients with hypercholesterolemia. J Clin Apher. 19(1):11-16, 2004   DOI   ScienceOn
31 良石主編. 秘方大全(名醫珍藏). 北京科學技術出版社, 2006
32 Paoletti, R., Fahmy, M., Mahla, G., Mizan, J. and Southworth, H. Rosuvastatin is superior to pravastatin and simvastatin in reducing low-density lipoprotein cholesterol, enabling more hypercholesterolemic patients to achieve low-density lipoprotein cholesterol targets. Am Coll Cardiol Annual Scientific Session, 2001
33 Shrestha, S., Volek, J.S., Udani, J., Wood, R.J., Greene, C.M., Aggarwal, D., Contois, J.H., Kavoussi, B., Fernandez, M.L. A combination therapy including psyllium and plant sterols lowers LDL cholesterol by modifying lipoprotein metabolism in hypercholesterolemic individuals. J Nutr. 136(10):2492-2497, 2006   DOI   PUBMED
34 Slowing, K., Ganado, P., Sanz, M., Ruiz, E., Tejerina, T. Study of garlic extracts and fractions on cholesterol plasma levels and vascular reactivity in cholesterol-fed rats. J Nutr. 131(3s):994S-999S, 2001   DOI   PUBMED
35 Sacks, F.M., Pfeffer, M.A., Moye, L.A., Rouleau, J.L., Rutherford, J.D., Cole, T.G., Brown, L., Warnica, J.W., Arnold, J.M., Wun, C.C., Davis, B.R., Braunwald, E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.N Engl J Med. 335(14):1001-1009, 1996   DOI   ScienceOn
36 Grundy, S.M. Approach to lipoprotein management in 2001 national cholesterol guidelines. Am J Cardiol 90 (suppl):11i-21i, 2002
37 小崎丈太郎. 小山千穂:特集　高脂血症治療の曲がり角　Nikkei Medical 6月号、pp 60-69, 1997
38 Tang, F.T., Qian, Z.Y., Liu, P.Q., Zheng, S.G., He, S.Y., Bao, L.P., Huang, H.Q. Crocetin improves endotheliumdependent relaxation of thoracic aorta in hypercholesterolemic rabbit by increasing eNOS activity. Biochem Pharmacol. 72(5):558-565, 2006   DOI   ScienceOn
39 Bocan, T.M., Krause, B.R., Rosebury, W.S., Lu, X., Dagle, C., Bak Mueller, S., Auerbach, B., Sliskovic, D.R. The combined effect of inhibiting both ACAT and HMG-CoA reductase may directly induce atherosclerotic lesion regression.Atherosclerosis. 157(1):97-105, 2001   DOI   ScienceOn
40 Lee, M.K., Moon, S.S., Lee, S.E., Bok, S.H., Jeong, T.S., Park, Y.B., Choi, M.S. Naringenin 7-O-cetyl ether as inhibitor of HMG-CoA reductase and modulator of plasma and hepatic lipids in high cholesterol-fed rats.Bioorg Med Chem. 11(3):393-398, 2003   DOI   ScienceOn
41 Adameova, A., Kuzelova, M., Faberova, V., Svec, P. The hypolipidemic effect of a new ACAT inhibitor, VULM 1457, in diabetic-hypercholesterolaemic rats. Pharmazie. 60(9):714-715, 2005   PUBMED
42 Freman, B.A. and Crapo, J.D. Biology of disease : Free radicals and tissue injury. Lab. Invest. 47: 412, 1982   PUBMED